{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:20:33Z","timestamp":1771471233022,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40122-018-0108-7","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T09:15:13Z","timestamp":1545124513000},"page":"67-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Role of Lofexidine in Management of Opioid Withdrawal"],"prefix":"10.1007","volume":"8","author":[{"suffix":"Jr.","given":"Joseph V.","family":"Pergolizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Annabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gharibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo Ann","family":"LeQuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"108_CR1","first-page":"148","volume":"103","author":"J O\u2019Shea","year":"2009","unstructured":"O\u2019Shea J, Law F, Melichar J. Opioid dependence. BMJ Clin Evid. 2009;103:148\u201354.","journal-title":"BMJ Clin Evid"},{"issue":"2","key":"108_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jsat.2014.03.004","volume":"47","author":"RD Weiss","year":"2014","unstructured":"Weiss RD, Potter JS, Griffin ML, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014;47(2):140\u20135.","journal-title":"J Subst Abuse Treat"},{"key":"108_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addbeh.2016.03.028","volume":"60","author":"MK Vernon","year":"2016","unstructured":"Vernon MK, Reinders S, Mannix S, Gullo K, Gorodetzky CW, Clinch T. Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification. Addict Behav. 2016;60:109\u201316.","journal-title":"Addict Behav"},{"key":"108_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"D Wesson","year":"2003","unstructured":"Wesson D, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoact Drugs. 2003;35:253\u20139.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"108_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1345\/aph.1M347","volume":"44","author":"EC Gish","year":"2010","unstructured":"Gish EC, Miller JL, Honey BL, Johnson PN. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother. 2010;44(2):343\u201351.","journal-title":"Ann Pharmacother"},{"key":"108_CR6","unstructured":"Drugs.com. Lofexidine hydrochloride. AHFS Monographs 2018. https:\/\/www.drugs.com\/monograph\/lofexidine-hydrochloride.html. Accessed 2 Oct 2018."},{"issue":"5","key":"108_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/00952990802308122","volume":"34","author":"E Yu","year":"2008","unstructured":"Yu E, Miotto K, Akerele E, et al. Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J Drug Alcohol Abuse. 2008;34(5):611\u20136.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8090","key":"108_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(78)92823-4","volume":"2","author":"MS Gold","year":"1978","unstructured":"Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. 1978;2(8090):599\u2013602.","journal-title":"Lancet"},{"issue":"8070","key":"108_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(78)90699-2","volume":"1","author":"MS Gold","year":"1978","unstructured":"Gold MS, Redmond DE Jr, Kleber HD. Clonidine in opiate withdrawal. Lancet. 1978;1(8070):929\u201330.","journal-title":"Lancet"},{"key":"108_CR10","first-page":"CD002024","volume":"2","author":"L Gowing","year":"2009","unstructured":"Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (Online). 2009;2:CD002024.","journal-title":"Cochrane Database Syst Rev (Online)"},{"issue":"8962","key":"108_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(95)92593-7","volume":"345","author":"S Cox","year":"1995","unstructured":"Cox S, Alcorn R. Lofexidine and opioid withdrawal. Lancet. 1995;345(8962):1385\u20136.","journal-title":"Lancet"},{"issue":"8a","key":"108_CR12","first-page":"972","volume":"32","author":"I Midgley","year":"1982","unstructured":"Midgley I, Chasseaud LF, Taylor T, Darragh A. The absorption and excretion of 14C-lofexidine hydrochloride in man. Arzneimittelforschung. 1982;32(8a):972\u20135.","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"108_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/00498258309052241","volume":"13","author":"I Midgley","year":"1983","unstructured":"Midgley I, Fowkes AG, Chasseaud LF, Hawkins DR, Girkin R, Kesselring K. Biotransformation of lofexidine in humans. Xenobiotica. 1983;13(2):87\u201395.","journal-title":"Xenobiotica"},{"issue":"1","key":"108_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/jps.21401","volume":"98","author":"AM Al-Ghananeem","year":"2009","unstructured":"Al-Ghananeem AM. Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. J Pharm Sci. 2009;98(1):319\u201326.","journal-title":"J Pharm Sci"},{"key":"108_CR15","unstructured":"US WorldMeds L. Advisory Committee Lofexidine hydrochloride (Lucemyra) briefing document. Psychopharmacologic drugs advisory committee 2018. https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM602419.pdf. Accessed 2 Oct 2018."},{"issue":"8a","key":"108_CR16","first-page":"955","volume":"32","author":"TH Tsai","year":"1982","unstructured":"Tsai TH, Beitman RE, Gibson JP, Larson EJ, Friehe H, Fontaine R. Acute, subacute and chronic toxicity\/carcinogenicity of lofexidine. Arzneimittelforschung. 1982;32(8a):955\u201362.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"108_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/00952990903060135","volume":"35","author":"AM Al Ghananeem","year":"2009","unstructured":"Al Ghananeem AM, Herman BH, Abbassi M, et al. Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. Am J Drug Alcohol Abuse. 2009;35(5):311\u20135.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"108_CR18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1517\/17460441.2014.962995","volume":"9","author":"AP Vartak","year":"2014","unstructured":"Vartak AP. The preclinical discovery of lofexidine for the treatment of opiate addiction. Expert Opin Drug Discov. 2014;9(11):1371\u20137.","journal-title":"Expert Opin Drug Discov"},{"key":"108_CR19","unstructured":"Lofexidine (Lucemyra) for opioid withdrawal. Med Lett Drugs Ther. 2018;60(1551):115\u20137."},{"issue":"2","key":"108_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.drugalcdep.2013.07.032","volume":"133","author":"SJ Kohut","year":"2013","unstructured":"Kohut SJ, Fivel PA, Mello NK. Differential effects of acute and chronic treatment with the alpha2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys. Drug Alcohol Depend. 2013;133(2):593\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"1554","key":"108_CR21","first-page":"137","volume":"60","author":"Management of opioid withdrawal symptoms","year":"2018","unstructured":"Management of opioid withdrawal symptoms. Med Lett Drugs Ther. 2018;60(1554):137\u201341.","journal-title":"Med Lett Drugs Ther"},{"issue":"11","key":"108_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1360-0443.1994.tb03745.x","volume":"89","author":"M Farrell","year":"1994","unstructured":"Farrell M. Opiate withdrawal. Addiction (Abingdon, England). 1994;89(11):1471\u20135.","journal-title":"Addiction (Abingdon, England)."},{"key":"108_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2017.02.020","volume":"176","author":"CW Gorodetzky","year":"2017","unstructured":"Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, Biswas K. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176:79\u201388.","journal-title":"Drug Alcohol Depend"},{"key":"108_CR24","first-page":"CD002024","volume":"5","author":"L Gowing","year":"2016","unstructured":"Gowing L, Farrell M, Ali R, White JM. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (Online). 2016;5:CD002024.","journal-title":"Cochrane Database Syst Rev (Online)"},{"issue":"1","key":"108_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/(SICI)1099-1557(200001\/02)9:1<43::AID-PDS466>3.0.CO;2-R","volume":"9","author":"JS Akhurst","year":"2000","unstructured":"Akhurst JS. Lofexidine in opiate withdrawal: a safety and usage survey. Pharmacoepidemiol Drug Saf. 2000;9(1):43\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1\u20132","key":"108_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.04.002","volume":"97","author":"E Yu","year":"2008","unstructured":"Yu E, Miotto K, Akerele E, et al. A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend. 2008;97(1\u20132):158\u201368.","journal-title":"Drug Alcohol Depend"},{"key":"108_CR27","first-page":"CD002021","volume":"5","author":"L Gowing","year":"2017","unstructured":"Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev (Online). 2017;5:CD002021.","journal-title":"Cochrane Database Syst Rev (Online)"},{"key":"108_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2018.04.012","volume":"91","author":"S Guo","year":"2018","unstructured":"Guo S, Manning V, Yang Y, et al. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: a double-blind randomized clinical trial in Singapore. J Subst Abuse Treat. 2018;91:1\u201311.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"108_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1592\/phco.29.5.495","volume":"29","author":"J Schmittner","year":"2009","unstructured":"Schmittner J, Schroeder JR, Epstein DH, Krantz MJ, Eid NC, Preston KL. Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study. Pharmacotherapy. 2009;29(5):495\u2013502.","journal-title":"Pharmacotherapy."},{"issue":"8","key":"108_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1592\/phco.27.8.1111","volume":"27","author":"JR Schroeder","year":"2007","unstructured":"Schroeder JR, Schmittner J, Bleiberg J, Epstein DH, Krantz MJ, Preston KL. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: a pilot study. Pharmacotherapy. 2007;27(8):1111\u20139.","journal-title":"Pharmacotherapy."},{"key":"108_CR31","unstructured":"National Collaborating Centre for Mental Health. Drug misuse: opioid detoxification: the NICE guideline. 2008. https:\/\/www.nice.org.uk\/guidance\/cg52\/evidence\/drug-misuse-opioid-detoxification-full-guideline-196515037. Accessed 2 Oct 2018."},{"issue":"3","key":"108_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/15622975.2011.561872","volume":"12","author":"M Soyka","year":"2011","unstructured":"Soyka M, Kranzler HR, van den Brink W, Krystal J, Moller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry. 2011;12(3):160\u201387.","journal-title":"World J Biol Psychiatry"},{"key":"108_CR33","unstructured":"Expanded table: some drugs for management of opioid withdrawal symptoms. Med Lett Drugs Ther. 2018;60(1554):e144\u2013e146."},{"issue":"1","key":"108_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jsat.2010.08.007","volume":"40","author":"E Day","year":"2011","unstructured":"Day E, Strang J. Outpatient versus inpatient opioid detoxification: a randomized controlled trial. J Subst Abuse Treat. 2011;40(1):56\u201366.","journal-title":"J Subst Abuse Treat"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-018-0108-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-018-0108-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-018-0108-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:41:14Z","timestamp":1724413274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-018-0108-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s40122-018-0108-7","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}